In metastatic clear cell renal cell carcinoma (ccRCC) and NSCLC patients, high basal sTIM-3 levels are associated with poor OS following anti-PD-1 monotherapy [146, 148]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.